Постановление Правительства Пермского края от 20.12.2017 № 1048-п

¦      ¦                                 ¦        ¦                          ¦                    ¦биологических лекарственных   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦препаратов под контролем      ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦микробиологического           ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦мониторирования, лабораторных ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦и инструментальных методов,   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦включая ультразвуковые        ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦исследования с доплерографией ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦сосудов печени,               ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦фиброэластографию и           ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦количественную оценку         ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нарушений структуры паренхимы ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦печени, биохимические,        ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦цитохимические                ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦(мониторирование содержания   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦панкреатической эластазы,     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦витаминов), лучевые методы (в ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦том числе                     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦ангиопульмонографию) и        ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦радиоизотопное сканирование   ¦            ¦

¦      +---------------------------------+--------+--------------------------+--------------------+------------------------------+            ¦

¦      ¦Поликомпонентное лечение         ¦  D80,  ¦иммунодефициты с          ¦терапевтическое     ¦поликомпонентное лечение      ¦            ¦

¦      ¦врожденных иммунодефицитов с     ¦ D81.0, ¦преимущественной          ¦лечение             ¦врожденных иммунодефицитов с  ¦            ¦

¦      ¦применением химиотерапевтических ¦ D81.1, ¦недостаточностью антител, ¦                    ¦применением                   ¦            ¦

¦      ¦и генно-инженерных биологических ¦ D81.2, ¦наследственная            ¦                    ¦химиотерапевтических и        ¦            ¦

¦      ¦лекарственных препаратов, под    ¦  D82,  ¦гипогаммаглобулинемия,    ¦                    ¦генно-инженерных              ¦            ¦

¦      ¦контролем                        ¦D83, D84¦несемейная                ¦                    ¦биологических лекарственных   ¦            ¦

¦      ¦молекулярно-генетических,        ¦        ¦гипогаммаглобулинемия,    ¦                    ¦препаратов под контролем      ¦            ¦

¦      ¦иммунологических и               ¦        ¦избирательный дефицит     ¦                    ¦молекулярно-генетических,     ¦            ¦

¦      ¦цитологических методов           ¦        ¦иммуноглобулина A,        ¦                    ¦иммунологических и            ¦            ¦

¦      ¦обследования                     ¦        ¦избирательный дефицит     ¦                    ¦цитологических методов        ¦            ¦

¦      ¦                                 ¦        ¦подклассов                ¦                    ¦обследования                  ¦            ¦

¦      ¦                                 ¦        ¦иммуноглобулина G,        ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦избирательный дефицит     ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммуноглобулина M,        ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммунодефицит с           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦повышенным содержанием    ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммуноглобулина M,        ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦недостаточность антител с ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦близким к норме уровнем   ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммуноглобулинов или с    ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦гипериммуноглобулинемией. ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦Преходящая                ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦гипогаммаглобулинемия     ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦детей. Комбинированные    ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммунодефициты. Тяжелый   ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦комбинированный           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммунодефицит с           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦ретикулярным дисгенезом.  ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦Тяжелый комбинированный   ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммунодефицит с низким    ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦содержанием T- и          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦B-клеток. Тяжелый         ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦комбинированный           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммунодефицит с низким    ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦или нормальным            ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦содержанием B-клеток.     ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦Общий вариабельный        ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммунодефицит             ¦                    ¦                              ¦            ¦

¦      +---------------------------------+--------+--------------------------+--------------------+------------------------------+            ¦

¦      ¦Поликомпонентное лечение         ¦  N04,  ¦нефротический синдром     ¦терапевтическое     ¦поликомпонентное              ¦            ¦

¦      ¦наследственных нефритов,         ¦N07, N25¦неустановленной этиологии ¦лечение             ¦иммуносупрессивное лечение    ¦            ¦

¦      ¦тубулопатий,                     ¦        ¦и морфологического        ¦                    ¦нефротического                ¦            ¦

¦      ¦стероидрезистентного и           ¦        ¦варианта, в том числе     ¦                    ¦стероидозависимого и          ¦            ¦

¦      ¦стероидзависимого нефротических  ¦        ¦врожденный, резистентный  ¦                    ¦стероидрезистентного синдрома ¦            ¦

¦      ¦синдромов с применением          ¦        ¦к кортикостероидному и    ¦                    ¦с применением селективных     ¦            ¦

¦      ¦иммуносупрессивных и (или)       ¦        ¦цитотоксическому лечению, ¦                    ¦иммуносупрессивных,           ¦            ¦

¦      ¦ренопротективных лекарственных   ¦        ¦сопровождающийся отечным  ¦                    ¦генно-инженерных              ¦            ¦

¦      ¦препаратов с морфологическим     ¦        ¦синдромом, постоянным или ¦                    ¦биологических лекарственных   ¦            ¦

¦      ¦исследованием почечной ткани     ¦        ¦транзиторным нарушением   ¦                    ¦препаратов под контролем      ¦            ¦

¦      ¦(методами световой, электронной  ¦        ¦функции почек,            ¦                    ¦иммунологических сывороточных ¦            ¦

¦      ¦микроскопии и                    ¦        ¦осложнившийся             ¦                    ¦и тканевых маркеров           ¦            ¦

¦      ¦иммунофлюоросценции) и           ¦        ¦артериальной              ¦                    ¦активности патологического    ¦            ¦

¦      ¦дополнительным                   ¦        ¦гипертензией,             ¦                    ¦процесса, а также             ¦            ¦

¦      ¦молекулярно-генетическим         ¦        ¦кушингоидным синдромом,   ¦                    ¦эффективности и токсичности   ¦            ¦

¦      ¦исследованием                    ¦        ¦остеопенией,              ¦                    ¦проводимого лечения           ¦            ¦

¦      ¦                                 ¦        ¦эрозивно-язвенным         ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦поражением                ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦желудочно-кишечного       ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦тракта, анемией,          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦неврологическими          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦нарушениями, склонностью  ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦к тромбообразованию,      ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦задержкой роста и         ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦иммунодефицитным          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦состоянием                ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦поликомпонентное              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦иммуносупрессивное лечение с  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦включением селективных        ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦иммуносупрессивных,           ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦генно-инженерных              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦рекобинантных и биологических ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦лекарственных препаратов при  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦первичных и вторичных         ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нефритах, ассоциированных с   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦коллагенозами и васкулитами,  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦под контролем лабораторных и  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦инструментальных методов,     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦включая иммунологические,     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦фармакодинамические, а также  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦эндоскопические,              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦рентгенорадиологические и     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦ультразвуковые методы         ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦диагностики                   ¦            ¦

¦      ¦                                 ¦        +--------------------------+--------------------+------------------------------+            ¦

¦      ¦                                 ¦        ¦наследственные            ¦терапевтическое     ¦поликомпонентное лечение при  ¦            ¦

¦      ¦                                 ¦        ¦нефропатии, в том числе   ¦лечение             ¦наследственных нефритах с     ¦            ¦

¦      ¦                                 ¦        ¦наследственный нефрит,    ¦                    ¦применением нефропротективных ¦            ¦

¦      ¦                                 ¦        ¦кистозные болезни,        ¦                    ¦и генно-инженерных            ¦            ¦

¦      ¦                                 ¦        ¦болезни почечных сосудов  ¦                    ¦биологических лекарственных   ¦            ¦

¦      ¦                                 ¦        ¦и другие, осложнившиеся   ¦                    ¦препаратов под контролем      ¦            ¦

¦      ¦                                 ¦        ¦нарушением почечных       ¦                    ¦лабораторных и                ¦            ¦

¦      ¦                                 ¦        ¦функций вплоть до         ¦                    ¦инструментальных методов,     ¦            ¦

¦      ¦                                 ¦        ¦почечной недостаточности, ¦                    ¦включая иммунологические,     ¦            ¦

¦      ¦                                 ¦        ¦анемией, артериальной     ¦                    ¦фармакодинамические, а также  ¦            ¦

¦      ¦                                 ¦        ¦гипертензией, инфекцией   ¦                    ¦рентгенорадиологические и     ¦            ¦

¦      ¦                                 ¦        ¦мочевыводящих путей,      ¦                    ¦ультразвуковые методы         ¦            ¦

¦      ¦                                 ¦        ¦задержкой роста,          ¦                    ¦диагностики                   ¦            ¦

¦      ¦                                 ¦        ¦нарушением зрения и       ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦слуха, неврологическими   ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦расстройствами.           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦Наследственные и          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦приобретенные             ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦тубулопатии,              ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦сопровождающиеся          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦нарушением почечных       ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦функций, системными       ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦метаболическими           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦расстройствами,           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦жизнеугрожающими          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦нарушениями               ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦водноэлектролитного,      ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦минерального,             ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦кислотно-основного        ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦гомеостаза, артериальной  ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦гипертензией,             ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦неврологическими          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦нарушениями, задержкой    ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦роста и развития          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦поликомпонентное лечение      ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦метаболических расстройств    ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦при канальцевых заболеваниях  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦почек в стадии почечной       ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦недостаточности с             ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦использованием цистеамина и   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦других селективных            ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦метаболических корректоров    ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦под контролем лабораторных и  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦инструментальных методов,     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦включая иммунологические,     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦цитохимические, а также       ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦рентгенорадиологические (в    ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦том числе двухэнергетическая  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦рентгеновская                 ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦абсорбциометрия) и            ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦ультразвуковые методы         ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦диагностики                   ¦            ¦

+------+---------------------------------+--------+--------------------------+--------------------+------------------------------+------------+

¦  32  ¦Поликомпонентное лечение         ¦ G12.0, ¦врожденные и              ¦терапевтическое     ¦поликомпонентное              ¦            ¦

¦      ¦рассеянного склероза,            ¦ G31.8, ¦дегенеративные            ¦лечение             ¦иммуномодулирующее лечение    ¦            ¦

¦      ¦оптикомиелита Девика,            ¦ P91.0, ¦заболевания центральной   ¦                    ¦нервно-мышечных, врожденных,  ¦            ¦

¦      ¦нейродегенеративных              ¦ P11.1, ¦нервной системы с         ¦                    ¦дегенеративных,               ¦            ¦

¦      ¦нервно-мышечных заболеваний,     ¦  G35,  ¦тяжелыми двигательными    ¦                    ¦демиелинизирующих и           ¦            ¦

¦      ¦спастических форм детского       ¦  G36,  ¦нарушениями, включая      ¦                    ¦митохондриальных заболеваний  ¦            ¦

¦      ¦церебрального паралича,          ¦  G60,  ¦перинатальное поражение   ¦                    ¦центральной нервной системы   ¦            ¦

¦      ¦митохондриальных                 ¦  G70,  ¦центральной нервной       ¦                    ¦иммунобиологическими и        ¦            ¦

¦      ¦энцефаломиопатий с применением   ¦  G71,  ¦системы и его             ¦                    ¦генно-инженерными             ¦            ¦

¦      ¦химиотерапевтических,            ¦  G80,  ¦последствия.              ¦                    ¦лекарственными препаратами,   ¦            ¦

¦      ¦генно-инженерных биологических   ¦ G81.1, ¦Ремиттирующий с частыми   ¦                    ¦на основе комплекса           ¦            ¦

¦      ¦лекарственных препаратов,        ¦  G82.4 ¦обострениями или          ¦                    ¦иммунобиологических и         ¦            ¦

¦      ¦методов экстракорпорального      ¦        ¦прогрессирующий           ¦                    ¦молекулярно-генетических      ¦            ¦

¦      ¦воздействия на кровь и с         ¦        ¦рассеянный склероз.       ¦                    ¦методов диагностики под       ¦            ¦

¦      ¦использованием прикладной        ¦        ¦Оптикомиелит Девика.      ¦                    ¦контролем лабораторных и      ¦            ¦

¦      ¦кинезотерапии                    ¦        ¦Нервно-мышечные           ¦                    ¦инструментальных методов,     ¦            ¦

¦      ¦                                 ¦        ¦заболевания с тяжелыми    ¦                    ¦включая иммунологические,     ¦            ¦

¦      ¦                                 ¦        ¦двигательными             ¦                    ¦биохимические, цитохимические ¦            ¦

¦      ¦                                 ¦        ¦нарушениями.              ¦                    ¦методы, а также методы        ¦            ¦

¦      ¦                                 ¦        ¦Митохондриальные          ¦                    ¦визуализации                  ¦            ¦

¦      ¦                                 ¦        ¦энцефаломиопатии с        ¦                    ¦(рентгенологические,          ¦            ¦

¦      ¦                                 ¦        ¦очаговыми поражениями     ¦                    ¦ультразвуковые методы и       ¦            ¦

¦      ¦                                 ¦        ¦центральной нервной       ¦                    ¦радиоизотопное сканирование)  ¦            ¦

¦      ¦                                 ¦        ¦системы. Спастические     ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦формы детского            ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦церебрального паралича с  ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦тяжелой двигательной      ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦инвалидизацией            ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦поликомпонентное лечение      ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нервно-мышечных, врожденных,  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦дегенеративных и              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦демиелинизирующих и           ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦митохондриальных заболеваний  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦центральной нервной системы   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦мегадозами кортикостероидов,  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦цитостатическими              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦лекарственными препаратами, а ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦также методами                ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦экстракорпорального           ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦воздействия на кровь, под     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦контролем комплекса           ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нейровизуализационных и       ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нейрофункциональных методов   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦обследования, определения     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦уровня сывороточных и         ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦тканевых маркеров активности  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦патологического процесса      ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦комплексное лечение тяжелых   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦двигательных нарушений при    ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦спастических формах детского  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦церебрального паралича,       ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦врожденных, включая           ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦перинатальные,                ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нейродегенеративных,          ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нервно-мышечных и             ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦демиелинизирующих             ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦заболеваниях с применением    ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦методов физиотерапии (в том   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦числе сочетанных методик      ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦криоэлектроимпульсной         ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦терапии, стимуляционных токов ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦в движении, основанных на     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦принципе биологической        ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦обратной связи),              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦кинезотерапии, механотерапии  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦и (или) ботулинотерапии под   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦контролем комплекса           ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нейровизуализационных и       ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦нейрофункциональных методов   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦обследования                  ¦            ¦

+------+---------------------------------+--------+--------------------------+--------------------+------------------------------+------------+

¦  33  ¦Поликомпонентное лечение тяжелых ¦  Е10,  ¦диабет новорожденных.     ¦                    ¦комплексное лечение тяжелых   ¦  186365,42 ¦

¦      ¦форм аутоиммунного и врожденных  ¦Е13, Е14¦Приобретенный             ¦                    ¦форм сахарного диабета и      ¦            ¦

¦      ¦моногенных форм сахарного        ¦        ¦аутоиммунный              ¦                    ¦гиперинсулинизма на основе    ¦            ¦

¦      ¦диабета и гиперинсулинизма с     ¦        ¦инсулинозависимый         ¦                    ¦молекулярно-генетических,     ¦            ¦

¦      ¦использованием систем суточного  ¦        ¦сахарный диабет,          ¦                    ¦гормональных и                ¦            ¦

¦      ¦мониторирования глюкозы и        ¦        ¦лабильное течение.        ¦                    ¦иммунологических исследований ¦            ¦

¦      ¦помповых дозаторов инсулина      ¦        ¦Сахарный диабет с         ¦                    ¦с установкой помпы под        ¦            ¦

¦      ¦                                 ¦        ¦осложнениями (автономная  ¦                    ¦контролем систем суточного    ¦            ¦

¦      ¦                                 ¦        ¦и периферическая          ¦                    ¦мониторирования глюкозы       ¦            ¦

¦      ¦                                 ¦        ¦полинейропатия,           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦нефропатия, хроническая   ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦почечная недостаточность, ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦энцефалопатия,            ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦кардиомиопатия,           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦остеоартропатия).         ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦Синдромальные моногенные  ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦формы сахарного диабета   ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦(MODY, DIDMOAD, синдром   ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦Альстрема,                ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦митохондриальные формы и  ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦другие), врожденный       ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦гиперинсулинизм           ¦                    ¦                              ¦            ¦

+------+---------------------------------+--------+--------------------------+--------------------+------------------------------+------------+

¦                                                        Сердечно-сосудистая хирургия                                                         ¦

+------+---------------------------------+--------+--------------------------+--------------------+------------------------------+------------+

¦  34  ¦Коронарная реваскуляризация      ¦ I20.1, ¦ишемическая болезнь       ¦хирургическое       ¦баллонная вазодилатация с     ¦  156544,16 ¦

¦      ¦миокарда с применением           ¦ I20.8, ¦сердца со стенозированием ¦лечение             ¦установкой стента в сосуд,    ¦            ¦

¦      ¦ангиопластики в сочетании со     ¦   I25  ¦1 - 3 коронарных артерий  ¦                    ¦сосуды                        ¦            ¦

¦      ¦стентированием при ишемической   ¦        ¦                          ¦                    ¦                              ¦            ¦

¦      ¦болезни сердца                   ¦        ¦                          ¦                    ¦                              ¦            ¦

+------+---------------------------------+--------+--------------------------+--------------------+------------------------------+------------+

¦  35  ¦Коронарная реваскуляризация      ¦ I20.1, ¦ишемическая болезнь       ¦хирургическое       ¦аортокоронарное шунтирование  ¦  221775,52 ¦

¦      ¦миокарда с применением           ¦ I20.8, ¦сердца со значительным    ¦лечение             ¦у больных ишемической         ¦            ¦

¦      ¦аортокоронарного шунтирования    ¦ I20.9, ¦проксимальным             ¦                    ¦болезнью сердца в условиях    ¦            ¦

¦      ¦при ишемической болезни и        ¦  I25,  ¦стенозированием главного  ¦                    ¦искусственного кровоснабжения ¦            ¦

¦      ¦различных формах сочетанной      ¦ I44.1, ¦ствола левой коронарной   ¦                    ¦                              ¦            ¦

¦      ¦патологии                        ¦ I44.2, ¦артерии, наличие 3 и      ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I45.2, ¦более стенозов коронарных ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I45.3, ¦артерий в сочетании с     ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I45.6, ¦патологией 1 или 2        ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I46.0, ¦клапанов сердца,          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I49.5, ¦аневризмой, дефектом      ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ Q21.0, ¦межжелудочковой           ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦  Q24.6 ¦перегородки, нарушениями  ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦ритма и проводимости,     ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦другими полостными        ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦операциями                ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦аортокоронарное шунтирование  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦у больных ишемической         ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦болезнью сердца на работающем ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦сердце                        ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦аортокоронарное шунтирование  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦в сочетании с пластикой       ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦(протезированием) 1 - 2       ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦клапанов                      ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦аортокоронарное шунтирование  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦в сочетании с                 ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦аневризмэктомией, закрытием   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦постинфарктного дефекта       ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦межжелудочковой перегородки,  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦деструкцией проводящих путей  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦и аритмогенных зон сердца, в  ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦том числе с имплантацией      ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦электрокардиостимулятора,     ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦кардиовертера-дефибриллятора, ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦другими полостными операциями ¦            ¦

+------+---------------------------------+--------+--------------------------+--------------------+------------------------------+------------+

¦  36  ¦Эндоваскулярная, хирургическая   ¦ I44.1, ¦пароксизмальные нарушения ¦хирургическое       ¦эндоваскулярная деструкция    ¦  177811,31 ¦

¦      ¦коррекция нарушений ритма сердца ¦ I44.2, ¦ритма и проводимости      ¦лечение             ¦дополнительных проводящих     ¦            ¦

¦      ¦без имплантации                  ¦ I45.2, ¦различного генеза,        ¦                    ¦путей и аритмогенных зон      ¦            ¦

¦      ¦кардиовертера-дефибриллятора     ¦ I45.3, ¦сопровождающиеся          ¦                    ¦сердца                        ¦            ¦

¦      ¦                                 ¦ I45.6, ¦сердечной                 ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I46.0, ¦недостаточностью,         ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I47.0, ¦гемодинамическими         ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I47.1, ¦расстройствами и          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I47.2, ¦отсутствием эффекта от    ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I47.9, ¦лечения лекарственными    ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦  I48,  ¦препаратами               ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I49.0, ¦                          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ I49.5, ¦                          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦ Q22.5, ¦                          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦  Q24.6 ¦                          ¦                    ¦                              ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦имплантация                   ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦частотно-адаптированного      ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦трехкамерного                 ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦кардиостимулятора             ¦            ¦

¦      ¦                                 ¦        ¦                          ¦                    +------------------------------+            ¦

¦      ¦                                 ¦        ¦                          ¦                    ¦торакоскопическая деструкция  ¦            ¦